BMO Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1300 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has reiterated its 'Outperform' rating for Regeneron Pharmaceuticals, maintaining a price target of $1300. Analyst Evan David Seigerman continues to see positive prospects for the company.
September 24, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has reiterated its 'Outperform' rating for Regeneron Pharmaceuticals, maintaining a price target of $1300. Analyst Evan David Seigerman continues to see positive prospects for the company.
The reiteration of an 'Outperform' rating and a high price target of $1300 by BMO Capital suggests confidence in Regeneron's future performance. This positive analyst sentiment is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100